Molecular Basis and Progress of Immunotherapy for Melanoma

Dear Colleagues,

The treatment landscape of melanoma is evolving beyond BRAF-targeted therapy and immune checkpoint inhibitors. Our improved understanding of cell survival pathways, chromatin remodeling, and DNA damage repair have led to major and critical observations that will lead to more targeted treatments based on individual tumor needs. Also, the field of immune therapies is expanding to more immune checkpoint inhibitors, cellular therapies (unmodified and modified), and bi-specific T cell engagers.

In this Special Issue, we will focus on the critical findings from basic, translational, and early clinical data that will hold promise in expanding our vision in this rapidly evolving field. Since IJMS is a journal of molecular science, pure clinical or model studies will not be suitable for our journal. However, clinical or pure model submissions with biomolecular experiments are welcomed.

Dr. George Ansstas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• melanoma
• immune checkpoint inhibitors
• immune therapies
• T cell
• NK cells